Novo Nordisk Draws Three Separate Verdicts — From a Texas Courtroom to the Buyback Ledger
Published on 10/24/2026 at 13:01 | Editorial boerse-global.de
Novo Nordisk picked up a procedural win in the United States this week, but the relief it offers investors is narrowly scoped. A federal judge in Texas declined to revive a lawsuit brought by Strive Specialties, the compounding pharmacy that had accused the Danish drugmaker and Eli Lilly of stifling competition in the GLP-1 market. The ruling keeps the case dismissed — and leaves the underlying commercial questions exactly where they were.
What the Texas Ruling Does and Doesn't Settle
Strive had asked the court to set aside an earlier dismissal of its complaint. U.S. District Judge James Wesley Hendrix refused, according to a Law360 report, leaving the suit closed in the Western District of Texas. The distinction matters: this was a bid to reopen a case already thrown out, not the resolution of a fresh antitrust action. The alleged blockade of competition remains an accusation by the plaintiff, not an established fact.
For shareholders, the decision removes one piece of legal noise without touching the earnings story. Whether Novo Nordisk can lift revenue and profit still turns on how its medicines sell, not on how a single litigant's procedural gambit fares.
A Volume Story Running Ahead of the P&L
On that commercial front, the picture is split. Oral Wegovy has been racking up prescriptions at a striking clip — roughly 5 million in its first six months on the U.S. market, equal to about 76% of the American oral obesity-treatment segment, according to figures attributed to Eric Fry. That is a dominant share of a fast-growing niche, and it is the kind of adoption curve product launches are judged against.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Yet the financial forecasts point the other way. Zacks models a revenue decline of about 3% for 2026 and a 14% drop in earnings per share — projections, not reported results. HSBC, meanwhile, trimmed its price target to DKK 280 from DKK 320 while keeping a hold rating on the stock. A product can win its category and still sit inside a company whose profit estimates are heading south; the two facts coexist without contradiction.
CagriSema: A Signal, With Caveats Attached
The pipeline offered its own data point on Tuesday, when Novo Nordisk presented additional findings from the REDEFINE 1 study of CagriSema. Women taking the investigational compound lost an average of 25.0% of body weight over 68 weeks, against 3.0% on placebo. The company also reported weight reductions among women before, during and after menopause, with the results unveiled at the annual meeting of the Menopause Society.
Read the fine print before extrapolating. The figures come from a post-hoc analysis conducted on a treatment-compliant basis — a methodological choice that shapes how far the numbers travel. And CagriSema remains a candidate in development; a headline weight-loss figure is not, by itself, a commercial outcome.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Buybacks: The Capital-Return Ledger
Separately from the science, Novo Nordisk updated its share repurchase disclosure on Monday. As of October 16, buybacks completed since February 4 totaled DKK 10,875,024,304. That sum reflects shares already purchased; the program itself authorizes up to DKK 15 billion over twelve months, a ceiling rather than a completed outlay.
Three threads, then, and each answers a different question. The court ruling closes off one avenue of litigation. The buyback report documents capital being returned. The CagriSema analysis adds supporting evidence for a drug still under development. None of them substitutes for the others — and the strong Wegovy uptake will only re-rate the equity once it shows up in the financials.
Ad
Novo Nordisk Stock: New Analysis - 24 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
